EP0661982A1 - Method for antagonizing inositol 1,4,5-triphosphate - Google Patents

Method for antagonizing inositol 1,4,5-triphosphate

Info

Publication number
EP0661982A1
EP0661982A1 EP93921252A EP93921252A EP0661982A1 EP 0661982 A1 EP0661982 A1 EP 0661982A1 EP 93921252 A EP93921252 A EP 93921252A EP 93921252 A EP93921252 A EP 93921252A EP 0661982 A1 EP0661982 A1 EP 0661982A1
Authority
EP
European Patent Office
Prior art keywords
inositol
triphosphate
binding
calcium
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP93921252A
Other languages
German (de)
English (en)
French (fr)
Inventor
Kenneth A. Stauderman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of EP0661982A1 publication Critical patent/EP0661982A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This application relates to a series of diamino benzenedisulfonic acid oligomers that have demonstrated an affinity for the receptor sites of inositol 1,4,5- triphosphate (IP 3 ) and are, therefore useful in diminishing the bioactivity of IP 3 , especially with regard to its effect on the release of intracellular calcium ions.
  • IP 3 inositol 1,4,5- triphosphate
  • IP 3 inositol 1,4,5-triphosphate
  • Inositol 1,4,5-triphosphate IP 3
  • IP 3 acts to stimulate the release of calcium ions from storage organelles within
  • IP 3 is characterized as a "second messenger".
  • the calcium released by IP 3 functions to stimulate a variety of physiologic processes such as smooth muscle contraction, histamine secretion and the hyperpolarization of nerve
  • Any compound or agent that can promote or interfere with the function of IP 3 will promote or interfere with the generation of calcium ions and thereby elicit predictable pharmacological effects.
  • IP 3 releases calcium ions begins with the binding of IP 3 to a specific receptor protein located on an intracellular calcium storage compartment located typically on the endoplasmic reticulum. This receptor protein has been cloned and has been shown to form
  • IP 3 binds with its receptor, a calcium channel is opened causing the release of calcium stored in the cell's endoplasmic reticulum. In turn, the released calcium will elicit the appropriate cellular response.
  • the diamino benzenedisulfonic acid oligomers of this invention also appear to antagonize the effects of IP 3 by competing for the receptor site. In most cases, these compounds are more effective than heparin and demonstrate fewer secondary effects.
  • these compounds are more effective than heparin and demonstrate fewer secondary effects.
  • the oligomers of this invention would also be administered to modulate IP 3 -induced calcium release and have a salutary effect on any number of disorders that are caused or exacerbated by an inordinately productive IP 3 second messenger pathway.
  • Specific binding was defined as the difference between total binding (radioactivity in the absence of test compound and cold IP 3 ) and non-specific binding
  • the y-axis represents the concentration of free calcium ions in arbitrary units.
  • the tracing shows that two successive additions of 0.1 ⁇ M of IP 3 stimulated similar amounts of calcium ion release from cerebellar microsomes.
  • the addition of 1 ⁇ M of MDL 102,869 stimulated a small increase of calcium ion for unknown reasons.
  • calcium ion release stimulated by 0.1 ⁇ M of IP 3 was inhibited by 42%. This inhibition was overcome by the addition of 1 ⁇ M of IP 3 , consistent with competitive antagonism by MDL 102,869.
  • n is a whole number within the range of 5-20 and the pharmaceutically acceptable salts thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EP93921252A 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate Ceased EP0661982A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95239392A 1992-09-28 1992-09-28
US952393 1992-09-28
PCT/US1993/008168 WO1994007507A1 (en) 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate

Publications (1)

Publication Number Publication Date
EP0661982A1 true EP0661982A1 (en) 1995-07-12

Family

ID=25492868

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93921252A Ceased EP0661982A1 (en) 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate

Country Status (13)

Country Link
EP (1) EP0661982A1 (es)
JP (1) JPH08502068A (es)
KR (1) KR950703347A (es)
AU (1) AU670962B2 (es)
CA (1) CA2145681A1 (es)
HU (1) HUT70192A (es)
IL (1) IL107066A (es)
MX (1) MX9305933A (es)
NO (1) NO951163L (es)
NZ (1) NZ256178A (es)
TW (1) TW260663B (es)
WO (1) WO1994007507A1 (es)
ZA (1) ZA936978B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000586A2 (en) * 1994-06-30 1996-01-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for treating cell proliferative disorders by modulating signal transduction
WO1996025157A1 (en) 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
TR199802694T2 (xx) * 1996-06-27 1999-03-22 Smithkline Beecham Corporation IL-8 resept�r kar��tlar�
TR199802695T2 (xx) 1996-06-27 1999-04-21 Smithkline Beecham Corporation IL-8 Resept�r kar��tlar�
CA2427757A1 (en) * 2000-11-09 2002-05-16 Contrimmune Biotechnology Inc. Therapeutic uses for ip3 receptor-mediated calcium channel modulators
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB781479A (en) * 1953-08-27 1957-08-21 Ciba Ltd New polyureas and process for making them
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEBS LETTERS, vol. 252, no. 1,2, 1989, pages 105-108; M.A. TONES ET AL.: 'THE EFFECT OF HEPARIN ON THE INOSITOL 1,4,5-TRISHOSPHATE RECEPTOR IN RAT LIVER NICROSOMES' *

Also Published As

Publication number Publication date
IL107066A (en) 1998-01-04
NO951163D0 (no) 1995-03-27
MX9305933A (es) 1994-04-29
ZA936978B (en) 1994-04-18
IL107066A0 (en) 1993-12-28
AU670962B2 (en) 1996-08-08
NZ256178A (en) 1997-03-24
WO1994007507A1 (en) 1994-04-14
KR950703347A (ko) 1995-09-20
CA2145681A1 (en) 1994-04-14
HUT70192A (en) 1995-09-28
TW260663B (es) 1995-10-21
JPH08502068A (ja) 1996-03-05
AU4841793A (en) 1994-04-26
HU9500891D0 (en) 1995-05-29
NO951163L (no) 1995-03-27

Similar Documents

Publication Publication Date Title
Akera Membrane Adenosinetriphosphatase: A Digitalis Receptor? The enzyme is a good model for receptor binding studies because of its known functional correlates.
Silveira et al. Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases
Burnstock Purinergic mechanisms
Ehlert The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium.
US5204329A (en) Treatment of organ transplantation rejection
TWI268923B (en) N6 heterocyclic 8-modified adenosine derivatives
McNeal et al. [3H] Batrachotoxinin A 20. alpha.-benzoate binding to voltage-sensitive sodium channels: a rapid and quanitative assay for local anesthetic activity in a variety of drugs
US20040006120A1 (en) Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
EP0661982A1 (en) Method for antagonizing inositol 1,4,5-triphosphate
Yatsu et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs
JP2002526443A (ja) 緑内障治療用セロトニン作動性５ｈｔ２作用物質
Kazmi et al. Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (μ) and enkephalin (δ) binding sites
JPH07502737A (ja) 複素環式化合物およびそれらの製法並びに使用
Ahlijanian et al. Antagonism of calmodulin-stimulated adenylate cyclase by trifluoperazine, calmidazolium and W-7 in rat cerebellar membranes.
Harris et al. Effects of dihydropyridine derivatives and anticonvulsant drugs on [3H] nitrendipine binding and calcium and sodium fluxes in brain
Atlas et al. Interaction of Clonidine and Clonidine Analogues with α‐Adrenergic Receptors of Neuroblastoma× Glioma Hybrid Cells and Rat Brain: Comparison of Ligand Binding with Inhibition of Adenylate Cyclase
WO1993023035A2 (en) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
JP2565762B2 (ja) グルカゴン同族体の合成とその治療用途
Coupet et al. Brain histamine H1-and H2-receptors and histamine-sensitive adenylate cyclase: effects of antipsychotics and antidepressants
Schettini et al. Somatostatin inhibition of anterior pituitary adenylate cyclase activity: different sensitivity between male and female rats
WO2002050080A1 (en) Small molecules useful in the treatment of inflammatory disease
Smith et al. Properties of concanavalin A-elicited granule exocytosis from human polymorphonuclear neutrophils
US7285528B2 (en) Agonists and antagonists of gonadotropin-releasing hormone-2, and use thereof
Lee et al. Potent enhancement of [3H] nitrendipine binding in rat cerebral cortical and cardiac homogenates: a putative mechanism for the action of MDL 12,330 A.
Onali et al. Identification and characterization of muscarinic receptors potentiating the stimulation of adenylyl cyclase activity by corticotropin-releasing hormone in membranes of rat frontal cortex

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19951009

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19960331